Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 01, 2020 08:00 ET | Source: Zogenix, Inc

Zogenix and Leading Experts to Present New Rare Epilepsy Data at AES 2020

New long-term safety, efficacy, and durability data for FINTEPLA® (fenfluramine) oral solution in Dravet syndromeFull results from Phase 3 study of FINTEPLA in Lennox-Gastaut syndrome New data from...
November 11, 2020 08:00 ET | Source: Zogenix, Inc

Zogenix to Participate in the Stifel 2020 Virtual Healthcare Conference

EMERYVILLE, Calif., Nov. 11, 2020 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq: ZGNX), a global biopharmaceutical company developing and commercializing rare disease therapies, today announced that...
November 09, 2020 16:01 ET | Source: Zogenix, Inc

Zogenix Provides Corporate Update and Reports Third Quarter 2020 Financial Results

FINTEPLA® (fenfluramine) oral solution launched in the U.S. in late July for Dravet syndrome with high enrollment of physicians and patients into the FINTEPLA Risk Evaluation and Mitigation Strategy...
October 29, 2020 08:00 ET | Source: Zogenix, Inc

Zogenix Announces Date Change for Third Quarter 2020 Financial Results and Conference Call and Webcast to November 9

EMERYVILLE, Calif., Oct. 29, 2020 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ: ZGNX), a global biopharmaceutical company developing rare disease therapies, today announced that it has changed the date...
October 26, 2020 08:00 ET | Source: Zogenix, Inc

Zogenix to Release Third Quarter 2020 Financial Results and Host Conference Call and Webcast on November 10

EMERYVILLE, Calif., Oct. 26, 2020 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ: ZGNX), a global biopharmaceutical company developing rare disease therapies, today announced that it will report its...
October 16, 2020 08:00 ET | Source: Zogenix, Inc

Zogenix Receives Positive CHMP Opinion for FINTEPLA® (Fenfluramine) Oral Solution for the Treatment of Seizures in Patients with Dravet Syndrome

Dravet syndrome is a rare, life-long, infant- and childhood-onset epilepsy associated with severe, treatment-resistant seizuresCHMP positive opinion based on Phase 3 study data that demonstrated...
October 15, 2020 16:16 ET | Source: Zogenix, Inc

Zogenix Presents New Data for FINTEPLA® in Dravet Syndrome at CNS 2020

Interim data from open-label extension trial showed substantial seizure reductions were maintained in patients treated with FINTEPLA® for up to two years Post-hoc analysis demonstrated NNTs (Number...
October 05, 2020 16:03 ET | Source: Zogenix, Inc

Zogenix, Inc. Announces Closing of Exercise by Initial Purchasers of Option to Purchase an Additional $30.0 Million of 2.75% Convertible Senior Notes Due 2027

EMERYVILLE, Calif., Oct. 05, 2020 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq: ZGNX), a global biopharmaceutical company developing rare disease therapies, today announced that the initial purchasers...
October 02, 2020 08:00 ET | Source: Zogenix, Inc

Zogenix Presents New Data at the World Muscle Society Conference 2020

EMERYVILLE, Calif., Oct. 02, 2020 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq: ZGNX), a global biopharmaceutical company developing and commercializing rare disease therapies, and its subsidiary Modis...
September 23, 2020 23:00 ET | Source: Zogenix, Inc

Zogenix, Inc. Prices $200.0 Million Convertible Senior Notes Offering

EMERYVILLE, Calif., Sept. 23, 2020 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq: ZGNX) today announced the pricing of its offering of $200,000,000 aggregate principal amount of 2.75% convertible senior...